Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China flag China · Delayed Price · Currency is CNY
10.43
+0.01 (0.10%)
Jul 31, 2026, 3:04 PM CST

SHE:000403 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
435.53770.161,3211,4291,001885.67
Trading Asset Securities
263.71254.39282.7423.34422.44234.21
Cash & Short-Term Investments
699.241,0251,6041,8531,4231,120
Cash Growth
-50.70%-36.12%-13.43%30.18%27.09%989.09%
Accounts Receivable
966.611,089710.69592.77891.08581.12
Other Receivables
8.449.176.542.3449.7112.83
Receivables
975.051,098717.19635.11940.79593.95
Inventory
1,7921,5781,245924.06623.69738.97
Prepaid Expenses
-18.9311.3712.350.140
Other Current Assets
84.141.241.611.8759.1216.53
Total Current Assets
3,5503,7213,5793,4263,0472,469
Property, Plant & Equipment
2,0462,0721,9991,5541,2971,103
Long-Term Investments
--6---
Goodwill
2,5362,5362,6152,6152,6152,615
Other Intangible Assets
187.16190.22200.33212.59192.52200.05
Long-Term Deferred Tax Assets
27.2826.5829.4349.0449.0927.35
Long-Term Deferred Charges
241.63229.9153.5579.4789.767.42
Other Long-Term Assets
793.92690.46664.24694.87692.81605.82
Total Assets
9,3839,4669,2468,6307,9827,088

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
133.71155.26224.26154.35158.37158.7
Accrued Expenses
35.33311.19335.48372.84373.49239.21
Short-Term Debt
536.31535.7310.49250.57275.1113.52
Current Portion of Long-Term Debt
75.1359.8417.0621.228.63-
Current Portion of Leases
-2.755.066.677.147.05
Current Income Taxes Payable
36.1715.5819.0739.7243.0824.22
Current Unearned Revenue
3.693.046.3610.7625.9111.54
Other Current Liabilities
232.3145.1239.266.0667.5888.04
Total Current Liabilities
1,0531,128956.97922.19959.31642.29
Long-Term Debt
161.85193.83303.22196.0852.89-
Long-Term Leases
13.811.9418.621.4829.5920.89
Long-Term Unearned Revenue
37.4836.9726.8435.640.0849.24
Long-Term Deferred Tax Liabilities
12.9613.8714.1324.2630.3336.52
Other Long-Term Liabilities
--99911.14
Total Liabilities
1,2791,3851,3291,2091,121760.07

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
950.4950.4731.07733732.39732.92
Additional Paid-In Capital
4,5394,5394,758-4,7794,779
Retained Earnings
2,6222,5992,4351,9461,392846.23
Treasury Stock
----43.17-36.22-32
Comprehensive Income & Other
0.030.040.054,7930.04-0
Total Common Equity
8,1118,0887,9257,4296,8686,326
Minority Interest
-7.02-6.78-7.15-6.79-6.42.07
Shareholders' Equity
8,1048,0817,9187,4226,8616,328
Total Liabilities & Equity
9,3839,4669,2468,6307,9827,088

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
787.09804.06654.44496.02373.36141.46
Net Cash (Debt)
-87.85220.48949.391,3571,050978.42
Net Cash Growth
--76.78%-30.02%29.22%7.30%-
Net Cash Per Share
-0.090.230.991.431.101.06
Filing Date Shares Outstanding
950.4950.4950.4950.06952.1952.8
Total Common Shares Outstanding
950.4950.4950.4950.34952.1952.8
Working Capital
2,4982,5932,6222,5042,0881,827
Book Value Per Share
8.538.518.347.827.216.64
Tangible Book Value
5,3885,3625,1104,6014,0603,511
Tangible Book Value Per Share
5.675.645.384.844.263.68
Buildings
-1,2661,180833.6701.14583.25
Machinery
-1,5631,184961.1920.37729.45
Construction In Progress
-225.99513.36582.7385.73334.38